CB
Highly rated in
21
conditions
Highly rated in
21
conditions
Check Dr. Christie M. Ballantyne's experience treating your condition:
About Dr. Christie M. Ballantyne

Christie Ballantyne is a Cardiologist in Houston, Texas. Ballantyne has been practicing medicine for over 40 years and is highly rated in 21 conditions, according to our data. His top areas of expertise are Atherosclerosis, High Cholesterol, Familial Hypertriglyceridemia, Coronary Artery Bypass Graft (CABG), and Heart Bypass Surgery. He is licensed to treat patients in Texas. Ballantyne is currently accepting new patients.

His clinical research consists of co-authoring 728 peer reviewed articles and participating in 6 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Christie M. Ballantyne it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Christie M. Ballantyne accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  UnitedHealthcare
  •  Superior HealthPlan
  •  Community Health

Call to see if your plan is accepted.
Locations
6655 Travis St, Suite 320, Houston, TX 77030
Background & Education
Graduate Institution
Baylor College Of Medicine, 1982
Specialties
Cardiology
Licenses
Internal Medicine in TX
Hospital Affiliations
CHI St Lukes Health - Baylor St Lukes Medical Center
Houston Methodist Hospital
Languages Spoken
English
Spanish
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention (The ELIMIT Trial)
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
View 4 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors